GVHD PROPHYLAXIS (NCCN HCT-B)
Prophylaxis by Donor Type
| Donor Setting | Preferred Regimens | Alternative Regimens |
| HLA-Matched (MSD or MUD) | • PTCy + Tacrolimus + MMF (Cat 1 for RIC — BMT CTN 1703) • CNI + MTX (Tacrolimus/MTX or Cyclosporine/MTX) • Tacrolimus + Sirolimus ± MTX | • PTCy + Cyclosporine (Cat 1 for RIC) • CNI + Abatacept + MTX (for MUD — ABA2 data) • ATG + CNI ± MTX or MMF • Alemtuzumab + CNI ± MMF or MTX • Ex vivo CD34 selection |
| Haploidentical (PREFERRED: PTCy-based) | • PTCy + Tacrolimus + MMF (STANDARD) • PTCy + Sirolimus + MMF | • Alemtuzumab + PTCy + Sirolimus or CNI • ATG + PTCy • Ex vivo CD34 selection or αβ T-cell depletion |
| HLA-Mismatched Unrelated (MMUD, PREFERRED: PTCy) | • PTCy + Tacrolimus + MMF • PTCy + Sirolimus + MMF • PTCy + Cyclosporine + Sirolimus | • CNI + Abatacept + MTX (7/8 MMUD) • ATG + PTCy • Ex vivo CD34 selection (7/8 MUD only) • Alemtuzumab + CNI ± MMF or MTX |
| Umbilical Cord Blood (UCB) | • CNI (Tacrolimus or Cyclosporine) + MMF (Standard for UCB — most experienced approach) | No PTCy standard for UCB at this time |
Key Clinical Trial Evidence
| Trial | Population / Result / Implication |
| BMT CTN 1703 (Bolanos-Meade, NEJM 2023) | RIC PBSC allo-HCT (MSD/MUD). PTCy + Tac + MMF vs. Tac + MTX. Result: superior 1-yr GVHD-free relapse-free survival (GRFS) with PTCy arm (52.7% vs 34.9%). Category 1 for RIC. |
| HOVON-96 (Broers, Blood Adv 2022) | Prospective randomized trial. PTCy + Cyclosporine for GVHD prophylaxis after HLA-matched PBSC. Category 1 for RIC. |
| ABA2 (Kean, Blood 2024) | Phase III: Abatacept + CNI + MTX in MUD and 1-allele MMUD (7/8). Significant reduction in severe aGVHD vs. CNI+MTX alone for MMUD. Abatacept FDA approved for aGVHD prophylaxis in MUD/MMUD. |
| MMUD PTCy Trial (Al Malki, JCO 2025) | Phase III: PTCy+Tac+MMF vs. standard (Tac+MTX) in MMUD PBSC. Superior 1-yr GRFS. Supports PTCy as preferred for MMUD. |
| Sirolimus/CSA/MMF (NMA) (Kornblit, Blood 2020) | Triple MMF/CSA/sirolimus superior to historical CSA/MMF in NMA with Flu/TBI 200–300 cGy + MMUD. |
PTCy Protocol Details
| Parameter | Details |
| Drug | Cyclophosphamide (post-transplant cyclophosphamide = PTCy) |
| Typical Dose | 50 mg/kg/day IV on Days +3 and +4 (post-transplant) |
| Mechanism | Eliminates rapidly proliferating alloreactive T-cells while sparing regulatory T-cells (Tregs) → tolerogenic immune reconstitution |
| Combination Partners | Tacrolimus (start Day +5) + MMF (start Day +5) — taper MMF often at Day +35, then CNI by Day +180 |
| ⚠ Conditioning Interaction | If Cy used in conditioning (e.g., Cy+TBI) AND PTCy planned: CAREFULLY evaluate total Cy dose — cumulative cardiac toxicity and hemorrhagic cystitis risk. |
| ⚠ Melphalan Interaction | If Mel used in conditioning + PTCy: carefully evaluate melphalan dose (NCCN footnote). PTCy pharmacokinetics may be affected. |
🔍 PHARMACIST WATCHPOINT: CNI TDM TARGETS: Tacrolimus typical trough 5–15 ng/mL (GVHD prophylaxis) — varies by institution and phase post-transplant. Cyclosporine 200–400 ng/mL. Check BEFORE dose and report critical values. CNIs + nephrotoxins (amphotericin, aminoglycosides, NSAIDs) → acute renal failure. Monitor CrCl and electrolytes (Mg, K) every 3–7 days in early post-transplant.
💎 CLINICAL PEARL: ABATACEPT PEARL: Abatacept is FDA-approved for aGVHD PROPHYLAXIS (not just treatment) in MUD and 1-allele MMUD transplantation. Combined with CNI+MTX backbone. For pharmacists: abatacept is dosed 10 mg/kg IV and has no significant drug interactions with CNIs — no TDM needed.
POST-TRANSPLANT FOLLOW-UP & COMPLICATIONS (NCCN HCT-C)
Post-Transplant Monitoring Framework
| Phase | Monitoring Focus | Pharmacist Actions |
| Early (<Day 30) | • Engraftment (ANC >500 × 2 days) • Mucositis, infections (bacterial esp.) • Organ toxicity (renal, liver, cardiac) • VOD/SOS risk surveillance • Hemorrhagic cystitis (if PTCy/Cy) | • Daily CBC, CMP, Mg, CMV PCR • Mucositis scale assessment • Dose-adjust CNIs, antimicrobials • Busulfan AUC if applicable • Mesna dosing if PTCy/Cy used |
| Day 30–100 | • GVHD (skin, GI, liver) • CMV/EBV/viral reactivations • Graft rejection/chimerism • Immune reconstitution | • CNI TDM, taper per protocol • CMV preemptive therapy if needed • Adjust immunosuppression • GVHD supportive care management |
| Late (>Day 100) | • Chronic GVHD • Late infections (PCP, Aspergillus) • Secondary malignancy • Endocrinopathies (thyroid, adrenal) • Bone health (DEXA) • Cardiovascular risk | • cGVHD medication management • Immunization schedule (avoid live vaccines) • Steroid-related AEs management • Survivorship medications |
Critical Early Complications with Pharmacotherapy Focus
VOD/SOS (Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome)
| Parameter | Details |
| Pathophysiology | Toxic injury to hepatic sinusoidal endothelium → fibrous obliteration → portal hypertension + hepatic congestion |
| Risk Factors | HD busulfan/TBI, prior liver disease, inotuzumab/gemtuzumab exposure, sirolimus + tacrolimus + MA conditioning, CIBMTR VOD score ≥2 |
| Classic Triad | 1. Painful hepatomegaly 2. Weight gain/ascites (>2% above baseline) 3. Jaundice (bilirubin >2 mg/dL) — within first 30 days post-HCT |
| EBMT Criteria (2016) | Classic VOD: <21 days post-HCT. Late-onset VOD: >21 days if etiology confirmed. Classic Triad OR 2 of 3 + histologic confirmation. |
| Treatment | DEFIBROTIDE (FDA-approved): For hepatic VOD/SOS with renal or pulmonary dysfunction. Dose: 6.25 mg/kg IV q6h × minimum 21 days Duration: until resolution or up to Day +60 |
| Defibrotide Monitoring | • Hypotension (most common) • Bleeding risk (hold if active bleeding) • Drug interactions: anticoagulants (additive bleed risk) • No formal dose adjustment for hepatic/renal dysfunction in package insert |
🔍 PHARMACIST WATCHPOINT: DEFIBROTIDE: Do NOT confuse with deferiprone or deferoxamine. Defibrotide has thrombolytic/anti-inflammatory activity. Watch for CONCURRENT anticoagulants (heparin flushes, prophylactic heparin). If patient needs heparin, discuss with team — defibrotide + anticoagulants = high hemorrhage risk.
Chimerism Monitoring (Allo-HCT)
- Complete donor chimerism: >95% donor cells in myeloid + lymphoid compartments
- Mixed chimerism: 5–95% donor cells
- Absent donor chimerism: <5% — high graft rejection/failure concern
- Declining chimerism in AML/MDS → signals relapse risk → alert team
- Monitor by peripheral blood PCR (STR-based, per NCCN HCT-2 update: STR genotyping required pre-transplant)
GVHD DIAGNOSIS, WORKUP & GRADING (NCCN GVHD-1/A/B/C)
Acute GVHD — Diagnosis & Workup (NCCN GVHD-1)
| Organ Suspected | Workup Steps |
| Skin Rash | Rule out drug rash, viral exanthem, engraftment syndrome. Skin biopsy of suspicious site. Discontinue potential offending drugs if possible. |
| Diarrhea / GI | Stool cultures, C. diff, CMV stool PCR. Lower GI biopsy (colonoscopy) — rectosigmoid biopsy has highest sensitivity + NPV. |
| Nausea / Vomiting | Consider upper GI biopsy (EGD). Rule out medications (MMF GI toxicity, voriconazole nausea), infections. |
| Liver (LFT Elevation) | Ultrasound / CT abdomen. Rule out: VOD/SOS, drug toxicity (azoles, CNIs), viral hepatitis reactivation (HBV, CMV). Liver biopsy if needed (transjugular if thrombocytopenic/coagulopathic). |
Acute GVHD Staging & Grading — Modified Glucksberg (Keystone) Criteria
| Stage | Skin | Liver (Bilirubin) | Gut (Diarrhea Volume/Day) |
| 1 | Rash <25% BSA | 2–3 mg/dL | >500 mL/day OR persistent nausea w/ histologic GVHD |
| 2 | Rash 25–50% BSA | 3–6 mg/dL | >1000 mL/day |
| 3 | Rash >50% BSA | 6–15 mg/dL | >1500 mL/day |
| 4 | Generalized erythroderma + bullae | >15 mg/dL | Severe abdominal pain ± ileus |
| Grade | Skin Stage | Liver Stage | Gut Stage |
| I (Mild) | 1–2 | None (0) | None (0) |
| II (Moderate) | 3 | 1 | 1 |
| III (Severe) | — | 2–3 | 2–4 |
| IV (Life-Threatening) | 4 | 4 | — |
Note: Grade IV may also include lesser organ involvement with extreme decrease in performance status.
MAGIC criteria also used (identical organs, slightly different staging thresholds — see GVHD-A 2 of 2). Minnesota Risk Score used for clinical trials (standard vs. high-risk).
Steroid-Response Definitions (NCCN GVHD-D)
| Definition | Acute GVHD Criteria | Chronic GVHD Criteria |
| STEROID-REFRACTORY | • Progression within 3–5 days of ≥2 mg/kg/day prednisone OR • No improvement after 5–7 days treatment OR • Incomplete response after >28 days IS therapy including steroids | • Progression on prednisone ≥1 mg/kg/day for 1–2 weeks OR • Stable disease on ≥0.5 mg/kg/day (or 1 mg/kg QOD) for 1–2 months |
| STEROID-DEPENDENT | • Cannot taper prednisone below 2 mg/kg/day OR • Recurrence during steroid taper | • Cannot taper below 0.25 mg/kg/day (or >0.5 mg/kg QOD) in ≥2 attempts separated by ≥8 weeks |
| STEROID-INTOLERANT | Emergence of UNACCEPTABLE TOXICITY from corticosteroids | Same definition |
ACUTE GVHD MANAGEMENT (NCCN GVHD-2/3)
Grade I aGVHD Management
Definition: Skin-only involvement, Stage 1–2 (<50% BSA, non-bullous rash), NO GI or liver involvement.
| First-Line Therapy | Details |
| Topical Steroids | Medium-to-high potency: Triamcinolone, Clobetasol. LOW potency (hydrocortisone) for face and intertriginous areas (avoid skin atrophy, telangiectasia). |
| Topical Tacrolimus | Alternative or add-on to topical steroids for refractory skin GVHD |
| Antihistamines | For pruritus/itching symptom relief — PRN. Not immunosuppressive. |
| Continue Original IS | Continue/restart original immunosuppressive agent(s) (CNI ± MMF etc.) |
| Observe | If asymptomatic and rash is STABLE — observation acceptable. Taper IS when resolved. |
If: Progression OR symptomatic (pruritus, pain, sloughing, increasing BSA) → treat as Grade II–IV aGVHD.
Grade II–IV aGVHD Management
| Clinical Scenario | First-Line Therapy |
| Upper GI ONLY (nausea, vomiting, anorexia) With skin ≤50% BSA Diarrhea <1000 mL/day | Prednisone 0.5 mg/kg/day + GI topical steroids (Beclomethasone dipropionate ± Budesonide) ⚠ Budesonide is LESS effective for upper GI tract |
| Skin, Lower GI, OR Liver Involvement Grade II (consider 1 mg/kg) Grade III–IV | Methylprednisolone (or equivalent): • Grade II: 1 mg/kg/day (consider 0.5–1 mg/kg) • Grade III–IV: 1–2 mg/kg/day ⚠ NO ROLE for escalation beyond 2 mg/kg/day OR Consider SIROLIMUS for standard-risk aGVHD (Ann Arbor 1/2 biomarkers, Minnesota standard-risk) |
⚠ NEVER add additional systemic agents to corticosteroids as FIRST-LINE therapy outside of a well-designed clinical trial. BMT CTN 0802 showed no benefit of adding MMF to steroids as first-line — ADDED no benefit and same infection risk.
Steroid-Refractory aGVHD — Second-Line Agents (NCCN GVHD-E)
| Agent | Dose / Route | NCCN Evidence Level | Key Toxicities / Pearls |
| RUXOLITINIB (JAKAVI®) | 10 mg BID PO (REACH2) Start 5 mg BID optional dose increase | CATEGORY 1 (FDA Approved) REACH1: ORR 55% | REACH2: ORR 62% vs 39% | • Thrombocytopenia (33%) • Anemia (30%) • CMV reactivation (26%) • Dose reduce for plt <100K • JAK1/2 inhibitor |
| ECP (Extracorporeal Photopheresis) | 8-methoxypsoralen + UVA. Weekly initially, taper. Facility/equipment dependent. | Category 2A Pooled ORR ~69–71% (systematic reviews) | • Very low AE rate • Delayed onset of effect • Best for SKIN (ORR 84%) • Logistically demanding |
| Ruxolitinib | See above | Category 1 | See above |
| Sirolimus | Target level 4–12 ng/mL Adjust based on TDM | Category 2A ORR 57–76% in retrospective studies | • TMA risk (esp. with tacrolimus) • Hyperlipidemia • Cytopenias • Proteinuria |
| MMF (Mycophenolate Mofetil) | 1–1.5g BID IV or PO | Category 2A ORR 31–48% retrospective | • GI toxicity (N/V/D) • Cytopenias • Less effective in high-grade |
| Tocilizumab (anti-IL-6R) | 8 mg/kg IV q2–4 weeks | Category 2A ORR 44–67%; CR 22–63% in lower GI | • Best for skin/GI • No response in liver • Infection risk • Available as biosimilar |
| Infliximab (anti-TNF) | 10 mg/kg IV weekly × ≥4 doses | Category 2A ORR 40–67% | • HIGH infection risk (81% bacterial) • Active TB screen before use • Caution with demyelinating disease |
| Vedolizumab | Standard IBD dosing (per institutional protocol) 300 mg IV q2 weeks × 3 then q8 weeks | Category 2A Meta-analysis ORR 60% at Day 28 Best as EARLY 2nd-line for GI GVHD | • Gut-specific — limited systemic IS • Lower infection risk vs others • Best results when used EARLY (2nd vs 3rd+ line) |
| ATG | Equine: 15 mg/kg/day × 5 days Rabbit: 2.5 mg/kg/day × 4–6 days | Category 2A ORR 54–59% | • Best for SKIN (CR 61% with skin) • Hepatic dysfunction risk • Profound lymphopenia • Infusion reactions |
| Basiliximab (anti-IL-2R) | 20 mg IV on Day 1 and Day 4 | Category 2A ORR 83% | • Best for skin (77%) • Liver GVHD poor responder (14%) • Chimeric monoclonal — no infusion precautions needed |
| Pentostatin | 1.5 mg/m²/day × 3 days, q2 weeks | Category 2A ORR 33–50% | • Avoid if hepatic GVHD (ineffective) • Renal dose adjustment CRITICAL • AUC-based exposure — excessive at reduced doses in renal dysfunction • Best <60yo with isolated lower GI |
| Alemtuzumab | 10 mg SC/IV daily × 5 days (Via Campath Distribution Program only in US) | Category 2A ORR 70–83% | • Profound lymphopenia • Infections in 78% • CMV surveillance essential • US access restricted |
| Etanercept (anti-TNF) | 25 mg SC BIW × 4 weeks then 25 mg weekly × 4 weeks | Category 2A ORR 46% | • Best for grade II and GI GVHD (64% GI response) • Lower infection risk vs infliximab |
| Alpha-1 Antitrypsin (AAT) | 60 mg/kg IV BIW × up to 4 weeks | Category 2A ORR 65%; CR 35% (Phase II) | • No grade 3–4 drug-related toxicities • No infusion reactions • Low infection mortality (10% at 6mo) |
| Remestemcel-L-rknd | 2 × 10⁶ cells/kg IV BIW × 4 weeks (Pediatric patients ≥2 months) | CATEGORY 2B FDA-approved in pediatric ONLY ORR 70.4% in Phase III Adult studies ONGOING | • Mesenchymal stromal cells • Well tolerated • Adults: investigational • No HLA matching needed • 86.8% Day 100 survival if responded |
💎 CLINICAL PEARL: RUXOLITINIB for SR-aGVHD: REACH2 (Phase III) showed 62% ORR vs 39% control (P<0.001) and longer median OS (11 vs 6.5 months). Dose is 10 mg BID. Monitor CBC biweekly — dose reduce if plt <100K: to 5 mg BID; hold if plt <50K or ANC <0.5K.
🔍 PHARMACIST WATCHPOINT: PENTOSTATIN IN RENAL IMPAIRMENT: Pentostatin is renally cleared. A phase II study showed EXCESSIVE drug exposure despite 50% dose reduction in patients with renal insufficiency. INEFFECTIVE for liver GVHD. Avoid if significant hepatic involvement or renal impairment. Monitor renal function throughout.
CHRONIC GVHD: DIAGNOSIS, GRADING & MANAGEMENT (NCCN GVHD-4/B/C/D/E)
Chronic GVHD Diagnosis — NIH 2014 Criteria (GVHD-B)
| Organ | Diagnostic (confirms cGVHD) | Distinctive (insufficient alone) | Common (both acute+chronic) |
| Skin | Poikiloderma; Lichen planus-like; Sclerotic; Morphea-like; Lichen sclerosus-like | Depigmentation; Papulosquamous lesions; Sweat impairment; Ichthyosis | Erythema; Maculopapular rash; Pruritus |
| Mouth | Lichen planus-like changes | Xerostomia; Mucoceles; Ulcers; Pseudomembranes | Mucositis; Erythema; Pain |
| Eyes | New dry/gritty eyes; Cicatricial conjunctivitis; KCS; Punctate keratopathy | Photophobia; Periorbital hyperpigmentation; Blepharitis | (None specific) |
| GI Tract | Esophageal web/stricture (upper to mid third esophagus) | Exocrine pancreatic insufficiency | Anorexia; Nausea; Diarrhea; Weight loss |
| Liver | Bili, Alk Phos >2× ULN; ALT >2× ULN | (No distinctive features) | (None specific) |
| Lung | BOS (biopsy-proven) OR clinical BOS criteria + other organ cGVHD | Air trapping/bronchiectasis on CT; COP; Restrictive lung disease | (None specific) |
| Genitalia | Lichen planus; Lichen sclerosus; Vaginal scarring; Phimosis; Urethral stenosis | Erosions; Fissures; Ulcers | (None specific) |
| Fascia/Joints | Fasciitis; Joint stiffness/contractures from fasciitis/sclerosis | Myositis/polymyositis (biopsy required) | Edema; Muscle cramps; Arthralgia |
BOS Diagnostic Criteria (lung cGVHD): (1) FEV1/VC <0.7 or <5th percentile; (2) FEV1 <75% predicted with ≥10% decline over 2 years; (3) No respiratory infection documented; (4) One supporting feature (air trapping on expiratory CT or elevated RV >120%).
NOTE: Biopsy NOT mandatory if patient has ≥1 DIAGNOSTIC finding. Biopsy required only for myositis/polymyositis confirmation.
NIH Global Severity of cGVHD (GVHD-C)
| Mild cGVHD | Moderate cGVHD | Severe cGVHD |
| 1–2 organs involved Max score 1 per organ Lung score 0 | ≥3 organs with max score 1 OR ≥1 organ (non-lung) score 2 OR Lung score 1 | ≥1 organ with score 3 OR Lung score 2 or 3 |
Key scoring notes: Skin — use HIGHER of BSA or skin feature score. Lung — use FEV1 score (not symptom score) for global severity calculation.
First-Line cGVHD Management (NCCN GVHD-4)
| Option | Details |
| Systemic Corticosteroids (Standard) | Prednisone/methylprednisolone 0.5–1 mg/kg/day. Initial dose varies by organs involved, severity, comorbidities, overlapping syndromes. |
| Sirolimus + Prednisone | Alternative to steroids alone. Randomized trial (Carpenter et al.): Prednisone + sirolimus = Prednisone + sirolimus + CNI (no added benefit from CNI). Lower renal dysfunction without CNI. Sirolimus level target: typically 3–12 ng/mL in cGVHD setting. |
| Topical Agents (organ-specific) | • Skin: Triamcinolone or clobetasol (medium-to-high potency). Low potency for face. • Oral: Dexamethasone rinse (swish and spit) or CNI rinse; dexamethasone gel • Eyes: Artificial tears, topical IS, autologous serum drops, punctal plugs, scleral lenses • Vaginal: Topical estrogen for vulvovaginal cGVHD • Lung (BOS): FAM (Fluticasone + Azithromycin + Montelukast) + inhaled steroids |
| FAM for Lung/BOS | Fluticasone (inhaled) + Azithromycin + Montelukast ⚠ Azithromycin ONLY for BOS TREATMENT — NOT prophylaxis (JAMA 2017: increased leukemia relapse + secondary neoplasms with azithromycin for BOS prophylaxis) |
Steroid-Refractory cGVHD — Second-Line Agents (NCCN GVHD-E)
| Agent | Dose | NCCN Level | Key Points / Watchpoints |
| RUXOLITINIB | 10 mg BID PO (REACH3) | CATEGORY 1 FDA Approved (cGVHD after 1–2 lines) | REACH3: ORR 50% vs 26% (P<0.001). FFS >19 vs 6 mo. Thrombocytopenia 15%, anemia 13%. |
| IBRUTINIB | 420 mg daily PO (adult) 240 mg/m²/day (ped <12y, max 420 mg) | Cat 2A, FDA Approved (After ≥1 prior line) | ORR 67–69% in adults. Multi-organ responder. ⚠ Hold 3–7 days pre/post surgery. ⚠ Afib risk (use with caution in cardiac patients). ⚠ Bleeding + anticoagulants. |
| BELUMOSUDIL (KD025) | 200 mg QD or BID PO | Cat 2A, FDA Approved (After ≥2 prior lines) ROCKstar trial | ORR 76%; CR 5%. Response in ALL organs including LUNG. Median DOR 54 weeks. 44% on belumosudil at >1 year. ROAK kinase inhibitor → anti-fibrotic. |
| AXATILIMAB-csfr (NKTERNAL®) | 0.3 mg/kg IV q2 weeks (Preferred dose per AGAVE-201) | Cat 2A, FDA Approved (After ≥2 prior lines) ≥40 kg only | AGAVE-201: ORR 74% at 0.3 mg/kg. CSF1R inhibitor (targets macrophage/monocyte pathway). AEs: headache, elevated LFTs, CK, infections. 60% maintained response at 12 months. |
| ECP | 8-MOP + UVA, individualized schedule | Category 2A Pooled ORR 64% | Best for SKIN (74%) and GI (53%). Lung ORR only 15–48% — not preferred for lung cGVHD. |
| Sirolimus | Target 3–12 ng/mL, adjust to TDM | Category 2A | TMA risk when combined with CNIs. Monitor renal function, lipids. |
| Rituximab | 375 mg/m² IV weekly × 4 | Category 2A (Best for cutaneous/fascia) | Best for cutaneous sclerosis. Phase II vs imatinib: similar response (~26–27%). Premedicate; monitor for infusion reactions. |
| Imatinib | 200–400 mg daily PO | Category 2A (Sclerotic/fibrotic cGVHD) | Best for SKIN sclerosis, joint ROM improvement. Anti-PDGFR activity. AEs: hypophosphatemia, edema, GI toxicity. Dose often limited by poor tolerability. |
| Hydroxychloroquine | 800 mg/day (12 mg/kg/day) PO | Category 2A (Skin, oral, liver cGVHD) | ORR 53%. ⚠ RETINAL TOXICITY with >2 years use. Annual ophthalmology monitoring REQUIRED. Not for GI cGVHD. |
| Low-dose MTX | 5–10 mg/m² PO weekly | Category 2A | Limited but supportive data. Mucositis risk. Monitor CBC, renal, LFTs. |
| Abatacept | 10 mg/kg IV per schedule (Phase I: MTD 10 mg/kg) | Category 2A (Phase I data) | 44% PR in Phase I. Best for mouth, GI, joints, skin, eyes, lungs. 51% steroid dose reduction. Pulmonary infections resolved. |
| Interleukin-2 (low-dose) | 0.3–1 × 10⁶ IU/m²/day SC | Category 2A | Expands Tregs → immunomodulatory. Durable responses in select patients. Injection site reactions. |
| Etanercept | 25 mg SC BIW × 4 weeks, then QW × 4 weeks | Category 2A (Lung/BOS benefit) | Best evidence for LUNG cGVHD/BOS. 32% clinical response in FEV1/FVC improvement. Low infection risk. |
| Pentostatin | 1 mg/m²/day IV × 3 days q3–4 weeks | Category 2A | Renal dose adjustment critical. Phase II ORR 55% in 53 patients (Jacobsohn 2007). |
💎 CLINICAL PEARL: BELUMOSUDIL (KD025) PEARL: It is the ONLY FDA-approved agent showing responses in PULMONARY cGVHD (BOS). Consider belumosudil for steroid-refractory cGVHD with lung involvement. ROCK2 kinase inhibitor acts downstream of TGF-β1 signaling — anti-fibrotic mechanism distinct from all other agents.
🔍 PHARMACIST WATCHPOINT: IBRUTINIB DRUG INTERACTIONS: Ibrutinib is a CYP3A4 substrate. Moderate-to-strong CYP3A4 inhibitors (voriconazole, posaconazole, fluconazole, diltiazem, clarithromycin) → INCREASE ibrutinib exposure → reduce ibrutinib dose per package insert. Voriconazole + ibrutinib: reduce to 140 mg/day. Posaconazole: reduce to 140 mg/day or hold. This is CRITICALLY IMPORTANT in HCT patients on antifungal prophylaxis.
GVHD SUPPORTIVE CARE (NCCN GVHD-F)
Supportive Care — All GVHD Patients
| Area | Recommendations |
| Antimicrobial Prophylaxis | Escalate as IS intensifies. PCP prophylaxis (TMP-SMX or alternative). Antifungal. Antiviral (acyclovir/valacyclovir for HSV/VZV). See NCCN Infections guidelines. |
| CMV Surveillance | Weekly CMV PCR in at-risk patients (CMV D+/R+ or R+ regardless of donor). Preemptive therapy if CMV reactivation (letermovir preferred first; ganciclovir/valganciclovir for treatment). |
| IVIG (Immunoglobulin) | Consider prophylactic IVIG in: UCB recipients, patients with cGVHD + recurrent sinopulmonary infections, B-cell deficiency-associated disorders. (NCCN GVHD-F update v1.2026) |
| Vaccination | AVOID live vaccines on immunosuppression or active GVHD. COVID-19 re-vaccination at 3 months post-transplant (CDC guidance). Inactivated vaccines schedule post-transplant per institutional protocol. |
| Steroid Complications | Monitor for: glucose intolerance, HTN, adrenal insufficiency, poor wound healing, myopathy, osteoporosis, vitamin D deficiency, mood changes. Start calcium + vitamin D supplementation. DEXA scan. |
| Bone Health | DEXA scan for current or past HD steroid exposure. Treat per result (bisphosphonates for osteoporosis). Monitor vitamin D levels. |
| Dermatology/Dental/Ophthalmology | Regular evaluations starting 6–12 months post-transplant. Dental evaluation for oral lesions (malignancy risk in cGVHD). |
| Ursodiol | May be considered for patients with liver GVHD (Ruutu et al.: ursodiol prophylaxis improved survival post-allo HCT). Also used for VOD/SOS prevention in high-risk patients. |
Acute GVHD-Specific Supportive Care
| Organ | Management |
| Skin GVHD | Avoid direct sunlight and photosensitizing agents. Use sunscreen. Dermatology consult for advanced disease. |
| GI GVHD — Diarrhea | Cautious use of opioids (ileus risk). Octreotide for diarrhea control — STOP once resolved or after 7 days (ileus risk). TPN + bowel rest for voluminous diarrhea. |
| GI Topical Steroids | Beclomethasone dipropionate (compounded) ± budesonide for upper GI aGVHD. ⚠ Monitor for adrenal insufficiency with prolonged use. |
| Nutrition | Protein-losing enteropathy → trace element deficiency (Mg, Zn) and vitamins (thiamine, B12, D). TPN if needed. Check thiamine if altered mental status. |
Chronic GVHD-Specific Supportive Care
| Organ | Management |
|---|---|
| Oral/Xerostomia | Sialagogues (cevimeline preferred — NCCN v1.2026 update) for severe xerostomia. Oral dexamethasone rinse or CNI rinse (swish and spit). Topical antifungal for oral thrush. |
| Eyes/KCS | Artificial tears (≥4×/day), topical tacrolimus eye drops, autologous serum drops, punctal plugs. Gas-permeable SCLERAL LENSES for severe. Cholinergic agents (cevimeline or pilocarpine) for severe sicca — UPDATED in GVHD-F v1.2026. |
| GI cGVHD | GI consult for esophageal stricture (periodic dilation). Pancreatic atrophy → malabsorption → oral pancreatic enzyme supplementation. |
| Genital cGVHD | Referral to dermatology, urology, or gynecology as appropriate. Topical estrogen for vulvovaginal cGVHD. Address erectile dysfunction, urinary symptoms. |
| Musculoskeletal/Lung | Physical therapy for sclerotic, musculoskeletal, neuromuscular involvement. Muscle relaxants/anti-spasmodics for cramps (UPDATED NCCN v1.2026). Lung cGVHD progressive after 2–3 lines → evaluate for LUNG TRANSPLANT. |
🔍 PHARMACIST WATCHPOINT: ORAL BECLOMETHASONE: Available as a COMPOUNDED agent only. It is NOT commercially available in the US in the GI-targeted formulation. Verify pharmacy can compound and that patient/caregiver receives proper administration instructions. Prolonged use → adrenal insufficiency — monitor HPA axis.
💎 CLINICAL PEARL: AZITHROMYCIN CAUTION: Per two randomized clinical studies (JAMA 2017; Biol Blood Marrow Transplant 2020), azithromycin used for BOS PROPHYLAXIS was associated with increased leukemia relapse and secondary neoplasms. NCCN explicitly recommends azithromycin only for BOS TREATMENT, not prophylaxis. Flag any prophylactic azithromycin orders in post-HCT patients.